CAJ | 학술논문

作为早期非小细胞肺癌治疗的一种治疗模式，体部立体定向放疗（SBRT）目前主要在非手术患者中应用。相比较传统分次小剂量照射，SBRT 采取单次大剂量照射，近年来临床研究主要集中在其有效的生物有效剂量等效换算模型及最佳剂量分割模式的探索，但尚未达成共识。研究表明 SBRT相较普通放疗在局部控制率、不良反应等方面具有一定优势，日后可应用于可手术患者。
작위조기비소세포폐암치료적일충치료모식，체부입체정향방료（SBRT）목전주요재비수술환자중응용。상비교전통분차소제량조사，SBRT 채취단차대제량조사，근년래림상연구주요집중재기유효적생물유효제량등효환산모형급최가제량분할모식적탐색，단상미체성공식。연구표명 SBRT상교보통방료재국부공제솔、불량반응등방면구유일정우세，일후가응용우가수술환자。
As one of the treatment options for early stage NSCLC,stereotactic body radiation therapy (SBRT)is mainly applied to the inoperable patients.Compared with small doses of traditional fractionated radi-ation treatment,SBRT are taken a single high dose of radiation.A large body of experience has been accumula-ted over the years and the mathematical model to describe survival in high dose range typically used in SBRT and the best dose of segmentation model were focused on,but there has not yet reached a consensus.Studies show that SBRT has certain advantages in local control ratio and adverse reaction compared with traditional radiotherapy,which can be used in operable patients in the future.